FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286382672> ?p ?o ?g. }

• W4286382672 abstract "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC). The use of capecitabine, an oral fluoropyrimidine pro-drug, is feasible and safe; hence, it provides an interesting alternative to 5-fluorouracil in the abovementioned regimen. This study aimed to evaluate the efficacy and safety of capecitabine, oxaliplatin, and irinotecan (XELOXIRI) regimen use with or without targeted drugs in Chinese patients with mCRC.We conducted a retrospective, longitudinal cohort study of patients with mCRC who received XELOXIRI regimen with or without targeted drugs (bevacizumab or cetuximab) every 2 weeks between January 2017 and November 2019 at the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences, and Peking Union Medical College. Treatment efficacy was assessed by investigators by evaluating the objective response rate (ORR) and disease control rate (DCR). Overall survival (OS) was assessed using Cox proportional hazards models. The adverse events were also analyzed.Sixty-one consecutive patients were examined and followed up for survival. As of November 8, 2021, the median follow-up time was 35.4 months. Disease progression and death occurred in 50 (82%) and 38 (62%) patients, respectively. The median treatment duration of XELOXIRI with or without bevacizumab or cetuximab was 10 cycles (range, 1-12 cycles). The median OS and PFS were 32.2 months (95%CI [24.8-39.6]) and 9.3 months (95% CI [8.1-10.5]), respectively. The ORR of 48 patients with measurable lesions was 70.8%, and the DCR was 89.6%. RAS/BRAF wild-type (HR 0.39; 95% CI [0.16-0.96], p = 0.04) and metastatic organs > 2 (HR 3.25; 95% CI [1.34-7.87], p = 0.009) were independent prognostic factors for OS. The incidence of any grade of adverse events (AEs) was 96.7% (59/61). Grade ≥ 3 AEs included neutropenia (19.7%), leukopenia (9.8%), diarrhea (3.3%), vomiting (3.3%), febrile neutropenia (1.6%), and thrombocytopenia (1.6%). No treatment-related death occurred.The use of the XELOXIRI regimen with or without a targeted drug was effective, with a manageable toxicity profile in Chinese patients with mCRC." @default.
• W4286382672 created "2022-07-22" @default.
• W4286382672 creator A5015195367 @default.
• W4286382672 creator A5016149701 @default.
• W4286382672 creator A5022474763 @default.
• W4286382672 creator A5026307948 @default.
• W4286382672 creator A5050437390 @default.
• W4286382672 creator A5053943040 @default.
• W4286382672 creator A5089797683 @default.
• W4286382672 date "2022-07-21" @default.
• W4286382672 modified "2023-09-27" @default.
• W4286382672 title "Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study" @default.
• W4286382672 cites W1764134105 @default.
• W4286382672 cites W1910716144 @default.
• W4286382672 cites W1934094702 @default.
• W4286382672 cites W1963586822 @default.
• W4286382672 cites W1985199765 @default.
• W4286382672 cites W1985645498 @default.
• W4286382672 cites W1986195579 @default.
• W4286382672 cites W1988082986 @default.
• W4286382672 cites W1989175303 @default.
• W4286382672 cites W1990423062 @default.
• W4286382672 cites W1990994894 @default.
• W4286382672 cites W1993780950 @default.
• W4286382672 cites W2044796029 @default.
• W4286382672 cites W2044970916 @default.
• W4286382672 cites W2046116942 @default.
• W4286382672 cites W2066040529 @default.
• W4286382672 cites W2066404804 @default.
• W4286382672 cites W2084470612 @default.
• W4286382672 cites W2103789431 @default.
• W4286382672 cites W2106845199 @default.
• W4286382672 cites W2125955619 @default.
• W4286382672 cites W2129998117 @default.
• W4286382672 cites W2135800465 @default.
• W4286382672 cites W2138926750 @default.
• W4286382672 cites W2140085392 @default.
• W4286382672 cites W2142436044 @default.
• W4286382672 cites W2142572653 @default.
• W4286382672 cites W2146161922 @default.
• W4286382672 cites W2147001311 @default.
• W4286382672 cites W2150266118 @default.
• W4286382672 cites W2166459387 @default.
• W4286382672 cites W2463198458 @default.
• W4286382672 cites W2465450966 @default.
• W4286382672 cites W2558788971 @default.
• W4286382672 cites W2561114892 @default.
• W4286382672 cites W2578423617 @default.
• W4286382672 cites W2596956169 @default.
• W4286382672 cites W2613375073 @default.
• W4286382672 cites W2622186675 @default.
• W4286382672 cites W2732193815 @default.
• W4286382672 cites W2765409795 @default.
• W4286382672 cites W2787981425 @default.
• W4286382672 cites W2792225300 @default.
• W4286382672 cites W2792494514 @default.
• W4286382672 cites W2792655657 @default.
• W4286382672 cites W2903585589 @default.
• W4286382672 cites W2954474595 @default.
• W4286382672 cites W2962862457 @default.
• W4286382672 cites W2964344676 @default.
• W4286382672 cites W2969591847 @default.
• W4286382672 cites W2980963825 @default.
• W4286382672 cites W2983994476 @default.
• W4286382672 cites W3007010344 @default.
• W4286382672 cites W3009139795 @default.
• W4286382672 cites W3032740927 @default.
• W4286382672 cites W3036855997 @default.
• W4286382672 cites W3094966287 @default.
• W4286382672 cites W3096616336 @default.
• W4286382672 cites W3161957147 @default.
• W4286382672 cites W3202457894 @default.
• W4286382672 cites W4214885494 @default.
• W4286382672 cites W4221028983 @default.
• W4286382672 cites W4239112513 @default.
• W4286382672 cites W4250935139 @default.
• W4286382672 doi "https://doi.org/10.1186/s12885-022-09889-3" @default.
• W4286382672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35864467" @default.
• W4286382672 hasPublicationYear "2022" @default.
• W4286382672 type Work @default.
• W4286382672 citedByCount "2" @default.
• W4286382672 countsByYear W42863826722023 @default.
• W4286382672 crossrefType "journal-article" @default.
• W4286382672 hasAuthorship W4286382672A5015195367 @default.
• W4286382672 hasAuthorship W4286382672A5016149701 @default.
• W4286382672 hasAuthorship W4286382672A5022474763 @default.
• W4286382672 hasAuthorship W4286382672A5026307948 @default.
• W4286382672 hasAuthorship W4286382672A5050437390 @default.
• W4286382672 hasAuthorship W4286382672A5053943040 @default.
• W4286382672 hasAuthorship W4286382672A5089797683 @default.
• W4286382672 hasBestOaLocation W42863826721 @default.
• W4286382672 hasConcept C121608353 @default.
• W4286382672 hasConcept C126322002 @default.
• W4286382672 hasConcept C141071460 @default.
• W4286382672 hasConcept C143998085 @default.
• W4286382672 hasConcept C167135981 @default.
• W4286382672 hasConcept C197934379 @default.
• W4286382672 hasConcept C2776694085 @default.
• W4286382672 hasConcept C2777802072 @default.
• W4286382672 hasConcept C2777909004 @default.

• next